Following the Hot Line session of the ESC Congress 2021 presented by George Dangas (New-York, USA), Daniele Giacoppo offers us a condensed version of this study.

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Mirvat Alasnag provides her take on the outcomes of small annuli sub-study from the FRANCE-TAVI Registry which included 1,195 patients. This trial was presented by Walid Ben-Ali at TCT 2022.